US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Amneal Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
AMRX
)
21.12
-0.27 (-1.26%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
July 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases 2023 Environmental, Social and Governance Report
June 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
↗
June 25, 2024
Here are three stocks to buy up 100% in the past year. Make sure you add these to your portfolio so that you can reap the benefits.
Via
InvestorPlace
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
June 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >